- Home
- SYNX vs SNSE Comparison
SYNX vs SNSE Comparison
Compare SYNX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- SNSE
- Stock Information
- Founded
- SYNX 2005
- SNSE 2005
- Country
- SYNX Israel
- SNSE United States
- Employees
- SYNX N/A
- SNSE 15
- Industry
- SYNX
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- SYNX
- SNSE Health Care
- Exchange
- SYNX Nasdaq
- SNSE Nasdaq
- Market Cap
- SYNX 11.3M
- SNSE 11.2M
- IPO Year
- SYNX 2024
- SNSE 2021
- Fundamental
- Price
- SYNX $1.60
- SNSE $9.00
- Analyst Decision
- SYNX
- SNSE Strong Buy
- Analyst Count
- SYNX 0
- SNSE 4
- Target Price
- SYNX N/A
- SNSE $72.50
- AVG Volume (30 Days)
- SYNX 145.2K
- SNSE 6.5K
- Earning Date
- SYNX 10-02-2025
- SNSE 11-13-2025
- Dividend Yield
- SYNX N/A
- SNSE N/A
- EPS Growth
- SYNX N/A
- SNSE N/A
- EPS
- SYNX N/A
- SNSE N/A
- Revenue
- SYNX $9,094,000.00
- SNSE N/A
- Revenue This Year
- SYNX $32.35
- SNSE N/A
- Revenue Next Year
- SYNX N/A
- SNSE N/A
- P/E Ratio
- SYNX N/A
- SNSE N/A
- Revenue Growth
- SYNX 19.14
- SNSE N/A
- 52 Week Low
- SYNX $1.41
- SNSE $5.00
- 52 Week High
- SYNX $6.49
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- SYNX 46.87
- SNSE 56.95
- Support Level
- SYNX $1.54
- SNSE $8.41
- Resistance Level
- SYNX $1.76
- SNSE $9.49
- Average True Range (ATR)
- SYNX 0.17
- SNSE 0.53
- MACD
- SYNX 0.00
- SNSE 0.07
- Stochastic Oscillator
- SYNX 25.68
- SNSE 70.76
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).